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Hepatitis C virus (HCV)-induced iron overload has been shown to promote liver fibrosis, steato-
sis, and hepatocellular carcinoma. The zonal-restricted histological distribution of pathological
iron deposits has hampered the attempt to perform large-scale in vivo molecular investigations
on the comorbidity between iron and HCV. Diagnostic and prognostic markers are not yet
available to assess iron overload-induced liver fibrogenesis and progression in HCV infections.
Here, by means of Spike-in SILAC proteomic approach, we first unveiled a specific membrane
protein expression signature of HCV cell cultures in the presence of iron overload. Computa-
tional analysis of proteomic dataset highlighted the hepatocytic vitronectin expression as the
most promising specific biomarker for iron-associated fibrogenesis in HCV infections. Next,
the robustness of our in vitro findings was challenged in human liver biopsies by immunohis-
tochemistry and yielded two major results: (i) hepatocytic vitronectin expression is associated
to liver fibrogenesis in HCV-infected patients with iron overload; (ii) hepatic vitronectin ex-
pression was found to discriminate also the transition between mild to moderate fibrosis in
HCV-infected patients without iron overload.
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1 Introduction
Liver fibrosis, the common outcome of chronic inflammatory
diseases, is the result of the wound-healing response of the
organ to repeated injury; this process causes distortion of the
hepatic architecture by forming a fibrous scar and nodules
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Our findings provide first observational evidences on the molecular
effects of viral-induced iron overload and allow for hypothesizing on
new diagnostic tools.
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of regenerating hepatocytes (liver cirrhosis), thus leading to
liver failure and eventually hepatocellular carcinoma (HCC)
[1]. Early diagnosis of fibrosis is crucial, and developing re-
liable diagnostic markers for its onset and progression is an
important goal in clinical hepatology.
Hepatitis C virus (HCV), estimated to chronically infect
more than 170 million individuals worldwide, is one of main
causes of liver fibrosis [2]. Commonly, in HCV-infected pa-
tients, liver fibrosis located in the portal tracts develops late
and remains stable over a long time [3]. However, in many
cases its onset and progression to cirrhosis is influenced
by comorbidity factors that include alcohol consumption,
metabolic syndromes, coinfections with human immunod-
eficiency virus, and hepatic iron overload [3, 4].
HCV-associated pathological iron deposits, ascribed to the
viral-induced inhibition of the iron regulatory hormone hep-
cidin, are observed in approximately 40% of chronic infec-
tions [5, 6]. Long-lasting iron overload exerts a negative in-
fluence on liver fibrosis [7–9]; it also been observed that iron
depletion therapy reduces the risk of developing severe fi-
brosis in HCV patients [10]. Iron-induced liver fibrosis is
principally attributable to oxidative damages [11]. In fact, the
increased production of ROS is responsible for severalmolec-
ular changes leading to the perturbation of normal cellular
morphology [12, 13]. In the viral-independent (e.g. genetic)
iron overload diseases, the iron deposits affect the entire
parenchyma and oxidative damage affects most of the hep-
atocytes [14]. On the contrary, in HCV infections iron de-
posits are observed almost exclusively in the periportal areas
and colocalize with the initial fibrous scars [15]. This limited
distribution has hampered in vivo molecular investigations
of the interaction between intracellular viral infection and
iron excess. Here, at aiming to identify potential early mark-
ers for the iron-induced liver fibrosis in HCV infections, we
circumvent this hindrance by firstly performing a “Spike-
in” stable-isotope labeling with amino acids in cell culture
(Spike-in SILAC) proteomic approach on HCV-infected cells
in presence of iron overload. A significant subset of specif-
ically modulated proteins was identified. A computational
analysis of proteomic datasets highlighted that the interac-
tion between viral infection and iron excess strongly upregu-
lates vitronectin expression. Our investigations on vitronectin
expression were then extended to in vivo samples. In partic-
ular, studies on human liver biopsies highlighted that hepa-
tocytic vitronectin production is an early molecular signature
of viral-associated liver fibrosis in presence of iron overload
and discriminates the transition between mild to moderate
fibrosis in HCV-infected patients.
2 Materials and methods
2.1 Ethics statement
The study has been approved by the ethics committee of
the INMI “L. Spallanzani” IRCCS, Rome, Italy, according to
the ethical guidelines of the 1975 Declaration of Helsinki.
Analyses on human liver biopsies and sera were carried out
on clinical samples and analyzed anonymously. To protect
patient confidentiality, all patient identifiers were removed
from the samples to make them completely anonymous.
2.2 Reagents
The chemicals, reagents, and suppliers that were used
are listed below: TEMED, SDS, Tween 20, BSA, PBS,
DMEM, trypsin-EDTA solution, FBS, L-glutamine, peni-
cillin/streptomycin, trifluoroacetic acid, Ponceau S solution,
-cyano-4-hydroxycinnamic acid, paraformaldehyde, Triton
X-100, sodium chloride, EDTA, protease inhibitor cocktail,
DTT, iodoacetamide, N-acetyl cysteine, and ammonium bi-
carbonate were purchased from Sigma-Aldrich (St. Louis,
MO). Bradford Bio-Rad Protein Assay, Page Ruler tm Plus
Prestained Protein Ladder Fermentas Life Sciences (Vilnius,
Lithuania). NuPAGE gel electrophoresis reagents Simply
Blue Safe Stain were obtained from Invitrogen (Carlsbad,
CA). SILAC media DMEM was purchased from Silantes
(Munich, Germany). Nytrocellulose membranes (Protran
BA85) were obtained from Whatman-Schleicher & Schuel
(Dassel, Germany). ECLPlusWestern BlottingDetection Sys-
tem was purchased from GE Healthcare (Chalfont St. Giles,
UK). Methanol and ACN were purchased from J.T. Baker
(Phillipsburg, NJ) and Microcolumn ZipTip (-C18) were
purchased from Millipore Corporation (Ballerica, MA). Anti
Vitronectin antibody was purchased from Santa Cruz (Dallas,
TX). Anti-GAPDH antibody and Membrane Protein Extrac-
tion Kit (M-PEK) were purchased from Calbiochem Merck
(Gibbstown, NJ).
2.3 In vitro production of the HCV infectious
particles and cell culture
The clone used for HCV particles production was the des-
ignated JFH-1, derived from a Japanese patient with ful-
minant hepatitis, kindly provided by Dr. T. Wakita [16, 17].
The highly permissive Huh7.5-derived cell line designated
Huh7.5.1 used for viral particles production was kindly pro-
vided by Prof. F. Chisari [18].
All cells were maintained in a monolayer at 37C in
5% CO2. For cell culture-derived HCV (HCVcc) production,
Huh7.5.1 cells were infected with JFH-1-derived virus (geno-
type 2a) (MOI = 0.1). In order to induce iron overload, after
5 day of cultivation, Huh7.5.1 cells were treated with iron
excess by means of FeSO4/8-Hydroxyquinoline 10 M for
30 min that has been shown to be nontoxic to cells [19]. After
6 days of cultivation, cells were lysed andmembrane proteins
were isolated following the Membrane Protein Extraction Kit
(M-PEK) protocol. Samples were analyzed by Bradford as-
say to determine the protein concentration, then dissolved in
SDS-loading buffer and analyzed by Western blotting.
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2.4 SILAC labeling of human-cultured hepatocytes
Huh7 5.1 cells and Huh7 5.1 treated cells (i.e.: iron overload,
HCV infection, or both conditions) were respectively grown
in SILAC “heavy” (13C6 15N4-arginine and 13C6-lysine) and
SILAC “light” (12C6 14N4-arginine and 12C6-lysine) conditions
for eight passages before the experiment. This period lasted
about 3 weeks, where the SILAC “heavy” cells’ labeling was
complete.
Equal amounts (150 g) of membrane proteins from
Huh7.5.1 and Huh7.5.1 treated with iron overload, HCV in-
fection or both the conditions were mixed and analyzed by
SDS-PAGE and nanoLC-MALDI. At least three independent
biological and technical replicates were performed.
2.5 Protein digestion, peptide purification, nanoLC
analysis, MS analysis
Hundred micrograms of membrane proteins obtained from
the SILAC experiment were separated on 4−12% gradient
gels (Invitrogen), stained by Simply Blue Safe Stain stain-
ing and visualized. Sixteen sections of the gel lane were cut.
Protein digestion of gel pieces, peptide purification, and LC-
MS/MS analysis were performed as previously described [20].
2.6 Data analysis
Matrix2png program (http://www.chibi.ubc.ca/matrix2png/)
was used for making heat-map visualizations of protein data
expression. Proteins were ordered through a hierarchical
Euclidean clustering algorithm using the Babelomics 4.2
(http://babelomics.bioinfo.cipf.es) [21]. Gene ontology anal-
ysis was performed by a functional profiling tool in Babe-
lomics 4.2. Right-tailed Fisher’s exact test was used to calcu-
late a p-value determining the probability that each biological
function and/or disease involved in that proteome profile al-
teration is due to chance alone. To identify the biomarkers
that are unique for the HCV + Fe cells, proteomic dataset for
each experimental condition were also analyzed by the IPA
biomarker comparison function.
2.7 Western blotting assay
Western blotting analyses were performed as described in
Mancone et al. [20].
2.8 Immunostaining
Immunohistochemical procedures were performed on
formalin-fixed paraffin-embedded tissue sections (4 m) ac-
cording to Carpenter et al. [22]. Santa Cruz Biotechnology
polyclonal rabbit Vitronectin 65/75 (H-270) was used as pri-
mary antibody (appropriately diluted 1:200). The sections
were evaluated by light microscopic examination and cellular
localization and intensity of immunostaining in each section
were assessed by two pathologist observers (A.B.; F.D.N.).
Individual cases were considered IR for individual antigens
whenmore than 5%of the cells were IR. IR cases were further
classified as follows: + = 5–10% IR cells; ++ = 11–50% IR
cells;+++ =>50% IR cells. Given the strong and consistent
expression of vitronectin immunoreactivity in the advanced
fibrotic liver hepatocytes, we also evaluated the staining in-
tensity of vitronectin as faint (+), moderate (++), and strong
(+++) in respect to non-IR hepatocytes. Histological assess-
ment of iron overload was performed by Perls’ Prussian blue
assay and the hepatocytic iron content (hepatocytic iron score)
was evaluated according to Deugnier’s grading [23].
2.9 Immunofluorescent microscopy
For immunofluorescence analysis, cells were fixed with 4%
paraformaldehyde, permeabilized with 0.2% Triton, blocked
with 10% donkey serum and then incubated with an anti-
CORE antibody (Anogen) and anti-Bip (Santa Cruz sc1051)
for 1 h. After beingwashed, cells were incubatedwithCyTM2-
conjugated AffiniPure F(ab’)2 fragment donkey anti-mouse
IgG (ImmunoResearch Laboratories, INC.) and Alexa Fluor
488 donkey anti-goat IgG (Invitrogen) secondary antibodies
for 30 min.
2.10 Real-time PCR
Cellular RNA was prepared with Trizol reagent (Invitrogen),
cDNA synthesis was generated from 1 g of RNA using
the reverse transcription kit (Promega) according to man-
ufacturer’s recommendations. Real-time PCR reactions were
performed with the LightCycler (Roche) using the LightCy-
cler FastStart DNA Master SYBR-Green-I (Roche) according
to the manufacturer’s instructions. Five microliters of 1:10
cDNA dilution cDNA was used as template and cycling pa-
rameters were 95C for 10 min, followed by 40 cycles of 95C
for 10 s, 62C for 10 s, 72C for 10 s. Relative amounts were
obtained using the 2−Ct method normalized for the L34
gene expression. Primer sets for all amplicons were:
HCVcc forward: 5′-TCTGCGGAACCGGTGAGTA-3′
HCVcc reverse: 5′-TCAGGCAGTACCACAAGGC-3′
L34 forward: 5′-GTCCCGAACCCCTGGTAATAG-3′
L34 reverse: 5′-GGCCCTGCTGACATGTTTCTT-3′
3 Results
3.1 Iron overload drastically perturbs the membrane
proteome profiles of cultured hepatoma cells
Morphological alterations of cell architecture in response to
injuries involve changes in cell surface protein expression and
in the specific release of secreted proteins. Therefore, both
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Figure 1. Spike in SILAC workflow. (A) Spike-in SILAC standard
labeling (Huh7.5.1 Heavy) was “decoupled” from the biological
experiments and then carried out under normal cell culture con-
ditions (Huh7.5.1 Light). Each treatment was performed and sub-
sequently analyzed in triplicate. (B) After the treatments were per-
formed, the nonlabeled samples were combined with the SILAC
standard and each of these combined samples was analyzed sep-
arately by LC-MS/MS. Ratio 1 originated from the light/heavy ratio
between iron-overloaded cells (Fe) and SILAC standard; Ratio 2
from HCV-infected cells (HCV) and SILAC standard; Ratio 3 from
iron-overloaded and HCV-infected cells (HCV + Fe) and SILAC
standard. Differences between the experimental samples were
calculated as the ‘ratio of ratios’, where the ratio of one sample
relative to the standard is divided by the ratio of the other relative
to the standard (Ratios 4 and 5).
the plasmamembrane and the intracellular secretory vesicles
represent a rich source for discovering novel biomarkers in
fibrogenesis.
In order to identify possible biomarkers of iron-induced
liver fibrosis in HCV infections, we performed a quantita-
tive proteomic analysis on highly native membrane purifi-
cations of HCV-infected cells (JFH-1 HCVcc) treated with
an excess of iron. In particular, we applied the Spike-in
SILAC strategy that allows for multiple quantitative com-
parisons among samples by means of a unique internal
standard (SILAC standard) [24]. To this end, we metabol-
ically labeled Huh7–5.1 cells with 13C6 15N4-arginine and
13C6-lysine (Heavy) for SILAC standard production. Nonla-
beled cell populations were instead grown in light medium
(12C6 14N4-arginine and 12C6-lysine) and subsequently subject
to HCV-infection with and without iron overload (Fig. 1A).
Notably, a previous study performed on a similar cell line
(Huh7.5) and HCV strain (J6/JFH1) demonstrated that HCV
infection at 1 and 3 days postinfection profoundly perturbs
the global proteome profile [25].We here therefore performed
our investigations at 6 days postinfection; this to avoid acute
phase-induced alterations in proteins expression and to ob-
tain a higher frequency of infected hepatocytes (Supporting
Information 1). Moreover, since previous reports performed
with subgenomic HCV replicon [26] and with HCV-infected
Huh7–5.1 cells (JFH-1 HCVcc) [27] systems indicated that
iron overload affects the expression of viral RNA and pro-
teins, we also investigated on HCV replication and infection.
In line with the published results, we found that iron ex-
cess downregulates intracellular viral RNA and core protein
antigen (Supporting Information 2).
Therefore, for proteomics analysis, cell extracts were iso-
lated separately and each nonlabeled sample was combined
with equal amounts of SILAC standard cell extract (Fig. 1B).
Finally, pooled samples were then enriched in plasma mem-
brane and the intracellular secretory vesicles (Supporting In-
formation 3) and isolated proteins were subsequently sub-
jected to nanoLC-MALDI-TOF/TOF analysis.
Among 803 detected proteins, 74, exhibiting abundance
changes 1.5-fold increase (Supporting Information 4) were
analyzed by means of a hierarchical clustering algorithm that
allowed for grouping similar samples based on the pattern
of fold-change in protein abundance (Babelomics 4.2). Then,
by using heat maps (Matrix2png, version 1.2.2), the protein
expression levels of HCV-infected cells with iron overload
(HCV + Fe, Ratio3) were compared with those of the two
conditions separately (Fe, Ratio1; HCV, Ratio2) (Fig. 2A).
Interestingly, while HCV at 6 days after infection only
partially modified protein expression, cells treated with iron
underwent dramatic changes in their membrane proteome
profiles. Since we were interested in proteins specifically
modulated when the HCV infection occurs in a context of
iron overload, we focused our attention on the protein pattern
in the HCV + Fe condition. To this end, we calculated the ra-
tios Fe/HCV (Ratio4) and (HCV + Fe)/HCV (Ratio5) (Fig. 1B
and Supporting Information 4). Interestingly, as shown in
Fig. 2B, the HCV + Fe profile shows a few but significant
differences in respect to the Fe profile (Fig. 2B). The gene on-
tology analysis revealed that the copresence of iron and HCV
causes impairment of the membrane proteome profile in a
broad range of biological processes, including cell–cell ad-
hesion, cell–extracellular matrix interactions, cell migration,
cell proliferation, and survival (Supporting Information 5).
3.2 Iron overload in HCV-infected cells causes
upregulation of vitronectin expression
To identify potential biomarkers specific for the comorbidity
betweenHCV and iron overload, the proteomic datasets were
then analyzed by the biomarker module of the IPA analysis
program. This application has led to ranking and prioritiza-
tion of the identified potential marker genes in HCV + Fe
cells. The membrane-associated vitronectin, a multifunc-
tional plasma and extracellular matrix protein produced
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Figure 2. Iron overload perturbs the proteome profile of the HCV-
infected cells. (A) Two-dimensional hierarchical clustering analy-
sis with a weighted Euclidean method of differentially regulated
proteins (Babelomics 4.2). Each horizontal row represents an in-
dividual condition and each vertical column an individual pro-
tein. Protein abundance ratios were colored according to the fold
changes (green Log10 ratios: downregulations; red Log10 ratios:
upregulations) and the color scale indicates the magnitude of ex-
pression changes. Black squares indicate no change in protein
abundance. The clustering tree is shown. (B) Heat map analysis
of Ratio4 and Ratio5. Each vertical column represents an individ-
ual protein. Protein abundance ratios were colored according to
the fold changes (green Log10 ratios: downregulations; red Log10
ratios: upregulations) and the color scale indicates the magni-
tude of expression changes. Black squares indicate no change in
protein abundance.
by hepatocytes, resulted as the top rank product (Table 1
and Supporting Information 6). This result was confirmed
and further extended by analyzing both membranes and
whole cell extract by Western blotting. As shown in Fig. 3,
Table 1. IPA biomarker comparison: top five proteins in common
biomarkers list
Gene name Protein name Fea) HCVa) HCV + Fea)
VTN Vitronectin 1.63 1.30 2.77
SLC3A2 4F2 cell-surface
antigen heavy chain
(CD98)
1.92 1.48 2.64
SLC1A5 Solute carrier family 1 1.50 2.10 2.24
KRT8 Cytokeratin-8 1.51 1.30 2.05
GNA13 Guanine nucleotide
binding protein
1.73 1.83 1.83
a) Fold change in respect to Silac standard.
vitronectin expression was found induced in HCV-infected
cells with iron overload, thus confirming proteomic results.
Since several reports characterized vitronectin as a reliable
immunomarker of mature liver fibrosis and hepatocellular
carcinoma [28–31], we decided to challenge the robustness of
this observation in HCV-infected patients.
3.3 Hepatocytic vitronectin production is an early
marker of iron associated-liver fibrosis in
HCV-infected patients
Forty paraffin-embedded formalin-fixed liver samples at dif-
ferent stages of liver fibrosis (F1–F4 according to Metavir
score) were collected from male treatment naı¨ve patients in-
fected with HCV genotype 1 (Table 2). HCV-related hepatic
iron accumulation has been shown to be present mainly in
male patients [5], and HCV genotype 1 has been shown to
be responsible for most of the chronic infections in Western
countries.
Samples were then assayed for HCV-related hepatocytic
iron overload and the vitronectin expression levels were then
evaluated by IHC analysis (Table 2). The results showed par-
ticular significance at the early stages of the fibrotic process:
while the vitronectin staining distribution was limited to the
portal tract connective tissue (Fig. 4A) in most of the non-
iron overload patients (HCV), all of the patients with in-
creased iron accumulation (HCV + Fe) showed intracellular
vitronectin immunostaining. In particular, the staining inten-
sity was found to be moderate or strong in the periportal hep-
atocytes and faint in the pericentral area (Table 2 and Fig. 4A).
Notably, staining for iron deposits highlighted the same pe-
culiar distribution. Overall, as shown in Fig. 4B, hepatocytic
vitronectin distribution colocalized with the pathological iron
deposits of the periportal area, and the hepatocytic iron score
was found to correlate with vitronectin staining intensity
(r = 0.79, p < 0.00003).
In advanced fibrosis (F3–F4), independent from iron accu-
mulation, both the hepatocytic and extracellular immunore-
activities were found increased in respect to those observed
in the early fibrotic stages (Table 2 and Fig. 4A). These data
indicate that the hepatic vitronectin expression also discrim-
inates the transition between mild to moderate fibrosis in
patients without iron overload. Conversely, no significant al-
terations in vitronectin plasma concentration were detected
(data not shown), maybe due to the high concentration levels
of circulating protein.
Altogether, these results indicate that hepatocytic vit-
ronectin expression shows a potential diagnostic yield in the
assessment of iron overload-associated liver fibrogenesis and
in discriminating disease progression (Fig. 4C).
4 Discussion
Currently, neither diagnostic nor prognostic tools are
available to assess the effects of HCV-related hepatic iron
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Figure 3. Vitronectin is upregulated in HCV-
infected cells with iron overload. Proteins from
membrane fractions andwhole cell extractswere
separated by SDS-PAGE and transferred to a
PVDF membrane. Vitronectin, GAPDH, and cal-
nexin were detected with respective antibod-
ies. Bands were analyzed by densitometry us-
ing Quality-One software (Bio-Rad laboratories,
Richmond, CA). The X axis shows the rela-
tive intensity of vitronectin/calnexin (A) and vit-
ronectin/GAPDH (B) in the indicated conditions.
All data were from at least three independent ex-
periments and shown as mean ± SD.
Table 2. Clinicopathological features and vitronectin immunohistochemical results of the series
Liver fibrosis
Metavir score
Patient Age Activity grade Hepatocytic iron
score
Vitronectin
immunoreactivity
Vitronectin
staining intensity
F1 1 54 3 0 / /
2 33 3 0 / /
3 41 3 0 / /
4 52 3 0 + +
5 30 3 0 / /
F1 6 57 3 9 + +
7 31 3 3 ++ ++
8 36 3 9 +++ +++
9 38 3 9 +++ ++
10 49 3 12 ++ ++
F2 11 52 3 0 + +
12 51 3 0 / /
13 48 3 0 / /
14 53 3 0 / /
15 44 3 0 + +
F2 16 55 3 6 + +
17 55 3 6 + +
18 51 3 18 +++ +++
19 43 3 6 ++ +
20 53 3 15 ++ ++
F3 21 33 3 0 +++ ++
22 61 3 0 +++ ++
23 47 3 0 ++ ++
24 49 3 0 ++ ++
25 47 3 0 ++ +
F3 26 51 3 6 +++ +++
27 48 3 3 ++ ++
28 61 3 18 +++ +++
29 50 3 6 ++ ++
30 52 3 6 ++ ++
F4 31 50 3 0 +++ ++
32 42 3 0 +++ ++
33 51 3 0 +++ +++
34 69 3 0 +++ +++
35 49 3 0 +++ +++
F4 36 55 3 9 +++ +++
37 55 3 3 +++ +++
38 53 3 3 +++ +++
39 51 3 3 ++ ++
40 50 3 9 +++ +++
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Figure 4. HCV-infected patients with hepatic iron overload already show hepatocytic vitronectin immunoreactivity in minimal and mild
fibrosis. (A) Vitronectin immunostaining on hepatic FFPE of HCV-infected patients with (HCV + Fe) and without (HCV) iron accumulation at
different stages of liver fibrosis (F1–F4). Portal tracts are indicated (P); squares indicatemagnifications showed in B. (Original magnifications
×10). (B) Vitronectin immunostaining and Perls’ Prussian blue assay on hepatic FFPE with (HCV + Fe) and without (HCV) iron accumulation
in the fibrotic stage F1. (Original magnifications ×40). (C) Histogram summarizing the mean values of vitronectin immunoreactivities (see
Table 2) of HCV-infected patients with (HCV + Fe) and without (HCV) hepatocytic iron accumulation.
accumulation on liver fibrosis onset and progression. Here,
combining in vitro and in vivo approaches, we identified the
vitronectin as a promising early marker of liver fibrosis in the
HCV infections with hepatic overload.
HCV-induced iron overload only regards a small number
of hepatocytes located in the periportal tract, thus limiting
a large-scale molecular investigation of in vivo samples. The
in vitro cellular model has been instrumental to this inves-
tigation. The introduction of the JFH-1 HCVcc natural in-
fection system has led to important advances in the study
of relationship between HCV and the host metabolism [17];
this in vitro model allowed for recapitulating a microenviron-
ment where the complete viral life cycle occurred in a con-
text of iron excess. The proteomic strategy Spike-in SILAC
led us to unveil a specific protein expression signature of
HuH7.5.1 cells in the presence of HCV, iron, and HCV and
iron. In fact, as Mann and coworkers showed, this extension
of the SILAC approach allows quantitative comparisons of
several different biological samples. A computational analy-
sis on proteomic datasets highlighted vitronectin as the most
promising specific biomarker for iron-induced fibrogenesis.
The correlation between hepatocytic vitronectin overexpres-
sion and HCV-induced hepatic iron overload was then chal-
lenged in human liver biopsies. This analysis highlighted two
major evidences; (i) hepatocytic vitronectin expression is asso-
ciated to liver fibrogenesis inHCV-infected patients with iron
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overload, (ii) hepatic vitronectin expression was found to dis-
criminate the transition between F2 and F3 fibrotic stages
also in patients without iron overload.
Vitronectin is a multifunctional glycoprotein produced by
hepatocytes, encapsulated in secretory vesicles, and released
in the extracellular space principally as serum protein and,
in the liver and in a variety of tissues, as component of
the extracellular matrix [32, 33]. This protein provides a
unique regulatory link among cell adhesion, differentiation,
proliferation, and morphogenesis: (i) it promotes cell pro-
liferation, spreading, and migration by interaction between
specific integrins, (ii) it is involved in the immune defense
through interaction with the complement system, and (iii)
it is implicated in the formation and dissolution of blood
clots [34].
Activated hepatic stellate cells (HSCs) have been identi-
fied as major collagen-producing cells in injured liver, thus
playing play a central role in the development of liver fibro-
sis [1]. In liver fibrogenesis, upregulation of v3 integrin,
a specific vitronectin receptor, contributes to the activation
and proliferation of HSC [35–37]. In addition, vitronectin is
involved in recruiting and positioning lymphocytes within
inflamed and malignant liver tissue, thus leading to HSC
activation [38]. In light of these evidences, it is conceivable
that increased hepatic vitronectin expression favors also the
fibrogenesis.
Vitronectin is found at low concentrations in normal extra-
cellular matrix and increased in chronic inflammatory liver
disease, where its deposition in ECM is indicative of mature
fibrosis [28–30]. Our results extend the potential diagnostic
yield of vitronectin in HCV-related liver fibrosis in presence
of iron overload. In fact, we highlighted an intracellular vit-
ronectin upregulation as early as in liver fibrosis stage F1.
Moreover, since in vitro and in vivo data were obtained with
different HCV genotype (i.e.: genotype 2 for JFH-1-derived
virus and genotype 1 for infected donors) it seems conceiv-
able that vitronectin upregulation is a general feature of HCV
infection.
In the last years several reports demonstrated that the
HCV-induced iron overload exerts a negative influence on
liver disease. In fact, iron accumulation induces liver steato-
sis (by increasing lipidogenesis and reducing intracellular
lipid catabolism and apoB-100-containing lipoprotein secre-
tion) and HCC [20, 39, 40]. Moreover, HCV-infected patients
with hepatic iron overload are at high risk of liver fibrosis:
hepatic iron excess has been positively correlated to fibrosis
progression (r = 0.356; p = 0.0003), to inflammatory activ-
ity (r = 0.248; p = 0.00121), to aspartate transaminase (r =
0.247; p= 0.0126), and indirectly to platelet count (r= –0.369;
p = 0.0002) [9]. In light of these observations, we believe that
monitoring and counteracting hepatic iron levels, so far only
considered within the framework of interferon-based therapy
[41], may be a valid antifibrotic strategy. In this context, the
assessment of hepatic vitronectin expression and its zonal
distribution could represent the read-out of the pathologi-
cal iron effects even at first stage of hepatic fibrosis; future
clinical investigations may challenge the robustness of these
insights.
In conclusion, we identified hepatocytic vitronectin as the
first iron-associated specific signature of liver fibrogenesis in
HCV infections. Our findings have implications for better
understanding the effects of iron as a comorbid factor of
chronic hepatitis C and suggest a potential clinical impact of
iron depletion therapy to counteract disease progression.
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